Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Takeda-Pharmaceutical-stellt-Ergebnisse-der-Phase-3-Studie-TOURMALINE-AL1-fur-NINLARO-bei-Patient-29698522/?utm_source=whatsapp&utm_medium=social&utm_campaign=share